PD173074

Licensed by Pfizer Catalog No.S1264

PD173074 Chemical Structure

Molecular Weight(MW): 523.67

PD173074 is a potent FGFR1 inhibitor with IC50 of ~25 nM and also inhibits VEGFR2 with IC50 of 100-200 nM in cell-free assays, ~1000-fold selective for FGFR1 than PDGFR and c-Src.

Size Price Stock Quantity  
In DMSO USD 98 In stock
USD 70 In stock
USD 120 In stock
USD 470 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 40 Publications

Purity & Quality Control

Choose Selective FGFR Inhibitors

Biological Activity

Description PD173074 is a potent FGFR1 inhibitor with IC50 of ~25 nM and also inhibits VEGFR2 with IC50 of 100-200 nM in cell-free assays, ~1000-fold selective for FGFR1 than PDGFR and c-Src.
Targets
FGFR1 [1]
(Cell-free assay)
VEGFR2 [1]
(Cell-free assay)
~25 nM 100 nM-200 nM
In vitro

PD173074 is an ATP-competitive inhibitor of FGFR1 with Ki of ~40 nM. PD173074 is also an effective inhibitor of VEGFR2. Compared to FGFR1, PD173074 weakly inhibits the activities of Src, InsR, EGFR, PDGFR, MEK, and PKC with 1000-fold or greater IC50 values. PD173074 inhibits autophosphorylation of FGFR1 and VEGFR2 in a dose-dependent manner with IC50 of 1-5 nM and 100-200 nM, respectively. [1] PD173074 inhibits FGF-2 promotion of granule neuron survival in a dose-dependent manner with IC50 of 12 nM, exhibiting 1,000-fold greater potency than that of SU 5402. [2] PD173074 specifically inhibits FGF-2-mediated effects on proliferation, differentiation, and MAPK activation in oligodendrocyte (OL) lineage cells. [3] PD173074 is active against the WT receptor and FGFR3 mutations in multiple myeloma (MM) cell lines. PD173074 also potently inhibits autophosphorylation of FGFR3 in a dose-dependent manner with IC50 of ~5 nM. PD173074 treatment potently reduces viability of FGFR3-expressing KMS11 and KMS18 cells with IC50 of <20 nM. Inhibition of aFGF-stimulated MM cell growth by PD173074 is highly correlated with the expression of FGFR3. PD173074 treatment completely abolishes NIH 3T3 transformation mediated by Y373C FGFR3 but not by Ras V12, demonstrating that PD173074 specifically targets FGFR3-mediated cell transformation and lacks nonspecific cytotoxic effect. PD173074 also induces functional maturation of KMS11 and KMS18 cells. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
NCI-H1581 NYPkblNOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmO3TWM2OD1yLkCxNlI2KM7:TR?= M322d3NCVkeHUh?=
KG-1 M164V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXCTWM2OD1yLkC1NVI6KM7:TR?= MWHTRW5ITVJ?
MFM-223 NF2yT4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTBwMkG1O|Yh|ryP MnrnV2FPT0WU
EoL-1-cell Mke3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3NWYRKSzVyPUCuN|I6QDRizszN NXrF[29[W0GQR1XS
ECC10 NUXtWnJpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTiTWM2OD1yLkOzPFk5KM7:TR?= NHixS|FUSU6JRWK=
H-EMC-SS NHLYS4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTBwM{S3NVUh|ryP M1jTNXNCVkeHUh?=
AN3-CA NUTr[ZFrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojaTWM2OD1yLkSwNVM{KM7:TR?= MkXLV2FPT0WU
HuO-3N1 NX70OJlrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jBWmlEPTB;MD61OFY2OyEQvF2= NUHHPIJQW0GQR1XS
RT-112 NYLkW|Y5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYi4T|V6UUN3ME2wMlU1PzBzIN88US=> M3jHTnNCVkeHUh?=
NEC8 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\1TWM2OD1yLkW2Nlg6KM7:TR?= NHu2cnFUSU6JRWK=
D-263MG MlqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHkWmZKSzVyPUCuO|EyPTlizszN M17EbnNCVkeHUh?=
SW962 M3jUUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUf3S|EyUUN3ME2wMlc5QTh6IN88US=> Mnf3V2FPT0WU
BV-173 M3LLUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfMcWZ1UUN3ME2wMlg1PjJ|IN88US=> NX2zbGlmW0GQR1XS
MFE-280 MoLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTBwOEW4O|Ih|ryP MVXTRW5ITVJ?
HuH-7 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXHTWM2OD1zLkK0OFY1KM7:TR?= M33nPXNCVkeHUh?=
RS4-11 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTFwM{O4PFYh|ryP NIrTbmhUSU6JRWK=
DMS-114 NU[3V4VUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorHTWM2OD1zLkO2O|M4KM7:TR?= NFfOSI9USU6JRWK=
MSTO-211H MnWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTFwNEezO|gh|ryP MorGV2FPT0WU
DU-145 NHjTXW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnodXNKUUN3ME2xMlU5OjF5IN88US=> NFvz[HJUSU6JRWK=
A172 NWD6PZRST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\qc3BKSzVyPUGuO|A{PTVizszN M4DrfXNCVkeHUh?=
SBC-1 NYrt[2hGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jhfGlEPTB;Mj6wPVQh|ryP M{C5VXNCVkeHUh?=
H9 M1T5emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTJwMUSzNFYh|ryP MUHTRW5ITVJ?
NCI-SNU-1 MojYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPRO4FTUUN3ME2yMlE5Ozl2IN88US=> M3\6N3NCVkeHUh?=
NCI-H720 NXjDSJd{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzofmdqUUN3ME2yMlIyOjh|IN88US=> MVzTRW5ITVJ?
HCC2218 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTJwM{e5N|kh|ryP M3ixZ3NCVkeHUh?=
G-401 M4T1XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlX4TWM2OD1{LkS3NVg6KM7:TR?= M3\ucXNCVkeHUh?=
MPP-89 NUHwXHdVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGi2TVNKSzVyPUKuOFg{PjRizszN M1jyfHNCVkeHUh?=
697 M1fIPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUOyTIRJUUN3ME2yMlY2OzNzIN88US=> MkW2V2FPT0WU
KARPAS-45 NIjB[W9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfZ[IxGUUN3ME2yMlcxPzR5IN88US=> M2\1OHNCVkeHUh?=
MG-63 MknDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnH5TWM2OD1{Lkm0NlYzKM7:TR?= NIXLfHNUSU6JRWK=
NTERA-S-cl-D1 MlHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHDW2JKSzVyPUOuNFM1PzJizszN Mn3FV2FPT0WU
G-402 Mk\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\zdotKSzVyPUOuNVI4OjdizszN MWjTRW5ITVJ?
NKM-1 NXfPNGZTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfz[4RnUUN3ME2zMlE{PTZ2IN88US=> M336PXNCVkeHUh?=
RH-18 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmX3TWM2OD1|LkG5OVk5KM7:TR?= NEXPUndUSU6JRWK=
NCI-H1092 NHPsdplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnMPIFOUUN3ME2zMlE6PjlizszN MWHTRW5ITVJ?
RPMI-8226 NILz[ohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4O4[2lEPTB;Mz6yN|Q1PyEQvF2= NELYNnZUSU6JRWK=
GAMG M{PiWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVn4enlVUUN3ME2zMlQ3PTd4IN88US=> M1XkcHNCVkeHUh?=
HH MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLYNHZKSzVyPUOuOFc3PzZizszN NF\pS5hUSU6JRWK=
RO82-W-1 NH;KRVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13GOWlEPTB;Mz60PVg2PSEQvF2= Ml\OV2FPT0WU
CCRF-CEM MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjyTWM2OD1|LkWwOFg5KM7:TR?= MlnGV2FPT0WU
NBsusSR Ml24S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnZcHdKSzVyPUOuOlM6PjlizszN NIHxWmVUSU6JRWK=
CHL-1 NWTaRVU1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETwOHBKSzVyPUOuOlU4QTlizszN MXPTRW5ITVJ?
LK-2 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TyUmlEPTB;Mz62O|E{OyEQvF2= NY\jdGUyW0GQR1XS
Hs-578-T MmTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;PTWM2OD1|Lk[3PFc{KM7:TR?= NV7xWFNPW0GQR1XS
CTB-1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mli0TWM2OD1|LkiwNFUyKM7:TR?= NXLQXGF5W0GQR1XS
ES5 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\2foMyUUN3ME2zMlg{PjN5IN88US=> MmPrV2FPT0WU
A204 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIqzZ4hKSzVyPUOuPVIxPzVizszN MljrV2FPT0WU
SW780 NF:wXmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnS5TWM2OD1|LkmyNlQ2KM7:TR?= MlfkV2FPT0WU
EW-3 NGf4fI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17WSmlEPTB;Mz65PFkzOyEQvF2= MonxV2FPT0WU
A704 NXTOUnc6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PYd2lEPTB;ND6yPFczOyEQvF2= MnTzV2FPT0WU
LU-139 MnThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTRwM{G1N|Qh|ryP MXXTRW5ITVJ?
CAL-72 Mmm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTRwNEG3OFYh|ryP MkXuV2FPT0WU
D-336MG NIDucGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LtOWlEPTB;ND60OlgyPyEQvF2= M1PiOnNCVkeHUh?=
LAMA-84 NYjnUVk4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTMU3NKSzVyPUSuOVM{OSEQvF2= Mn7FV2FPT0WU
GI-ME-N MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;hOXVJUUN3ME20MlU1QDFizszN NWTkdJR3W0GQR1XS
KM-H2 M3zDSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2CwS2lEPTB;ND61OVIzOiEQvF2= MmrGV2FPT0WU
NCI-H209 NVPsd4xNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvzRW5KSzVyPUSuOVgzQDNizszN NXrMe4RkW0GQR1XS
IGROV-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTRwOEexOlgh|ryP Mor3V2FPT0WU
L-363 Mmj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7yV4pPUUN3ME20Mlk3PjZ3IN88US=> NYPJZYo4W0GQR1XS
SK-MEL-3 NYTqT4E1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTqO3VqUUN3ME21MlI1ODZizszN MY\TRW5ITVJ?
HuO9 NV22N|EzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XpXGlEPTB;NT6zPFg1OyEQvF2= NX\CSJp1W0GQR1XS
NOS-1 NX7JOHNMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\m[2JFUUN3ME21MlczQTJ5IN88US=> NGr6cFNUSU6JRWK=
NCI-H1770 M4K5dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTVwOUWwN|Ih|ryP NYXsV4hUW0GQR1XS
SF126 Mn\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTZwMkG0NFYh|ryP NETu[o5USU6JRWK=
ML-2 M4D2VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTZwMkS5O|ch|ryP M2nX[XNCVkeHUh?=
CHP-134 NHfpXZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrBZo9KSzVyPU[uNlUyQDJizszN NFrMVlFUSU6JRWK=
NCI-H1355 Ml3hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTZwNEG3N|Mh|ryP MYTTRW5ITVJ?
TE-12 NGfBSXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTZwN{K2O|Eh|ryP NFPCTW1USU6JRWK=
A4-Fuk NX3HTnY3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTZwN{OxOFIh|ryP NHrDeFhUSU6JRWK=
MV-4-11 NUm5c3lmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUC2eoN6UUN3ME22Mlc3PjJ4IN88US=> MkTNV2FPT0WU
SK-UT-1 MlvsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TWd2lEPTB;Nj65NVc5PCEQvF2= NYHxVFB2W0GQR1XS
J-RT3-T3-5 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrDTWM2OD15LkC3O|Y1KM7:TR?= NH6zdpRUSU6JRWK=
ME-180 M4W3Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTdwMUC0NFQh|ryP MUTTRW5ITVJ?
SK-MEL-28 M3HQWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHITWM2OD15LkO3PFE6KM7:TR?= NVjpfnNmW0GQR1XS
HAL-01 NEjISZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPITWM2OD15LkS4N|QyKM7:TR?= M{GxdnNCVkeHUh?=
ES8 NWnX[YdlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTdwNkm2NlYh|ryP MofZV2FPT0WU
DB MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rNNGlEPTB;OD6xNVUxPCEQvF2= NXvuS217W0GQR1XS
SK-NEP-1 NIrL[lBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRThwNEixOFkh|ryP MnzPV2FPT0WU
COR-L88 NVXBd|AyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlraTWM2OD16LkWwPVgyKM7:TR?= NYi3PGE1W0GQR1XS
LB1047-RCC NX\5XGY4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn62TWM2OD16LkWyNlEzKM7:TR?= NYG5[lJFW0GQR1XS
NCI-H520 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfEOW9KSzVyPUiuOlIyPTdizszN MUHTRW5ITVJ?
SW954 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX2wcFVSUUN3ME24MlY6Pzh4IN88US=> NX\KUGhDW0GQR1XS
TE-6 M3z2cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTueWpuUUN3ME24Mlc2OTR|IN88US=> M2jVZ3NCVkeHUh?=
D-283MED MkC0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTlwME[1N|Qh|ryP MY\TRW5ITVJ?
DBTRG-05MG MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTlwMEm2NFch|ryP NYS0V2d3W0GQR1XS
NCI-H446 NYTDTXdNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTlwMkm1NlYh|ryP MW\TRW5ITVJ?
HOS NIDqOG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH[4U|BKSzVyPUmuN|UyOzRizszN MkjNV2FPT0WU
ES4 NID5[4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;ZbG9UUUN3ME25MlUxPTl3IN88US=> MWPTRW5ITVJ?
EW-13 M{PLS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjTXVRoUUN3ME25Mlg6ODV3IN88US=> MkfRV2FPT0WU
IST-MES1 M4m5cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILvd4FKSzVyPUmuPVQ2OzRizszN NYHoWm9MW0GQR1XS
CAS-1 NUnzZWpjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTlwOUe2OVkh|ryP MX;TRW5ITVJ?
EM-2 NVP0Xmo1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PDNWlEPTB;MUCuNVM6OyEQvF2= M4\SdXNCVkeHUh?=
SW948 Mn;ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrnXWtKSzVyPUGwMlE5QDJizszN MmjwV2FPT0WU
OAW-42 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTFyLkWyOlch|ryP MlrPV2FPT0WU
BE-13 NF\GVXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PZe2lEPTB;MUCuOlU4PiEQvF2= NGPCWFFUSU6JRWK=
KU812 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnpcWk1UUN3ME2xNE44OzlzIN88US=> MUjTRW5ITVJ?
SK-MEL-30 MkjpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjXc4I4UUN3ME2xNE45QTBzIN88US=> NXuzW41oW0GQR1XS
A2780 M{LZXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HqfGlEPTB;MUGuNFMxQCEQvF2= NVPUWVYzW0GQR1XS
TGBC24TKB M3LKbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHEZ45WUUN3ME2xNU4xPzN5IN88US=> NF7Te2pUSU6JRWK=
GOTO Mo\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInw[2VKSzVyPUGxMlIxQDRizszN NGPwb5hUSU6JRWK=
NCI-H526 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPCWpF6UUN3ME2xNU4{QDN5IN88US=> Mnf4V2FPT0WU
BHT-101 M3PoPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTFzLkS0OVYh|ryP NWPERZVlW0GQR1XS
NCI-H1155 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTFzLkS5OFch|ryP NVfNUYREW0GQR1XS
MCF7 NHTIToFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnFfpZKSzVyPUGxMlYyPjdizszN NHXsS|FUSU6JRWK=
MKN45 NITrcoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPIbZdKSzVyPUGxMlc6QTNizszN Mm\zV2FPT0WU
MOLT-16 NED4U2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVv6WHdYUUN3ME2xNU46Pjl{IN88US=> MljnV2FPT0WU
YH-13 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTF{LkCzOFYh|ryP MWrTRW5ITVJ?
P12-ICHIKAWA NV6ze|g2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvZTWM2OD1zMj6zPFQ2KM7:TR?= M2D4bXNCVkeHUh?=
GR-ST MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;4TWM2OD1zMj61Nlk2KM7:TR?= NXHvd3VbW0GQR1XS
CAKI-1 NVLhXXdWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;CWm9PUUN3ME2xNk44QTFizszN MX3TRW5ITVJ?
LXF-289 M3vhS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXOfGJKSzVyPUGzMlA5OzVizszN NELjXm1USU6JRWK=
MHH-PREB-1 NH7J[GpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3f3R2lEPTB;MUOuNlcxPCEQvF2= NGDnZ4JUSU6JRWK=
EW-16 NXfpd|lzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPiTWM2OD1zMz6zNVg4KM7:TR?= MX7TRW5ITVJ?
NCI-H82 M4nnWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXPTWM2OD1zMz60NVk2KM7:TR?= MXLTRW5ITVJ?
MMAC-SF NWjEWpVKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\uVVdKSzVyPUGzMlQ2PDdizszN MmjEV2FPT0WU
COLO-684 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXL0PJNbUUN3ME2xN{42OzF6IN88US=> MW\TRW5ITVJ?
QIMR-WIL MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPXVoFKSzVyPUGzMlgyODlizszN NH7VOnZUSU6JRWK=
NB69 MoGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTF|Lkm4Olgh|ryP Mn71V2FPT0WU
NCI-H2291 Mk\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTF2LkS0OVMh|ryP MYPTRW5ITVJ?
MKN7 M3rkeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PsbGlEPTB;MUSuOlY4PiEQvF2= NFfiOVZUSU6JRWK=
HDLM-2 NUXQSoVVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTF3LkGyPFYh|ryP NVTSfnpYW0GQR1XS
A253 NEDlW4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrkTWM2OD1zNT6zPFY6KM7:TR?= MmTwV2FPT0WU
SK-LU-1 M3LneGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3n2e2lEPTB;MUWuPVA6PCEQvF2= NEPnZnBUSU6JRWK=
MEG-01 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTF3LkmxNFch|ryP NEjnc5BUSU6JRWK=
SK-N-DZ Mo\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HhdmlEPTB;MUWuPVM4PiEQvF2= NGX6bpNUSU6JRWK=
H4 NX7sW4trT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnr2TWM2OD1zNj6wPFgh|ryP MlzQV2FPT0WU
LU-65 NEjT[HpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTF4LkOzPFQh|ryP NYHt[pJqW0GQR1XS
NCI-H1048 M2f1e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTF4LkWxOlUh|ryP MXLTRW5ITVJ?
LCLC-97TM1 Moi4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTmSVBEUUN3ME2xOk42QDh7IN88US=> NIKzOXlUSU6JRWK=
CAL-120 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFW5b2JKSzVyPUG2Mlk5PzlizszN NHLvUpJUSU6JRWK=
LU-134-A MlnES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUK2XFZHUUN3ME2xO{4{OzlzIN88US=> M1T4[HNCVkeHUh?=
SK-MEL-1 NFjQfFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LYe2lEPTB;MUeuO|EzPyEQvF2= M1;ETHNCVkeHUh?=
NCI-H69 NFzIW|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmG3TWM2OD1zNz65N|A4KM7:TR?= NE[yWldUSU6JRWK=
MC116 M1rIfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFO5WXNKSzVyPUG3Mlk4PSEQvF2= MYLTRW5ITVJ?
UMC-11 M3TOZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUW3WphMUUN3ME2xPE4yPzh6IN88US=> Mnq1V2FPT0WU
HCC1395 MkDHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjuTWM2OD1zOD60N|AyKM7:TR?= M4WwVXNCVkeHUh?=
no-10 M2PzOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTF6Lk[zPFgh|ryP NYG0Tm1PW0GQR1XS
NY M4PnWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTF7LkC4NFkh|ryP MXvTRW5ITVJ?
OS-RC-2 M1rNXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnTboRtUUN3ME2xPU4yOjV{IN88US=> NYrGTWdbW0GQR1XS
D-423MG M1fK[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnDRmV3UUN3ME2xPU4{QTV{IN88US=> MmO5V2FPT0WU
LC-2-ad MnK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjx[HVDUUN3ME2xPU44PjF{IN88US=> NIHxbJBUSU6JRWK=
DU-4475 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXK5N3NmUUN3ME2xPU45QDV{IN88US=> Mk\UV2FPT0WU
YKG-1 NFG1PIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLSTWM2OD1zOT65OlIh|ryP MnrrV2FPT0WU
HCC1569 NFLsZpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDvdmIzUUN3ME2yNE4zPjJ2IN88US=> NX7VSpRNW0GQR1XS
TYK-nu M3fqU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonsTWM2OD1{MD6yPFQ4KM7:TR?= M4ruU3NCVkeHUh?=
DEL MorCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTITWM2OD1{MD65PFA5KM7:TR?= MV3TRW5ITVJ?
MHH-ES-1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrJPJhkUUN3ME2yNU4{PTl5IN88US=> MonUV2FPT0WU
KARPAS-299 MkXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2THS2lEPTB;MkGuOVI6KM7:TR?= NXPJ[GdrW0GQR1XS
CTV-1 M3y3Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\xTWM2OD1{MT62NVczKM7:TR?= MWXTRW5ITVJ?
NCI-H2452 NH\5NZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHpTWM2OD1{Mj62Olc4KM7:TR?= NHv1PVdUSU6JRWK=
D-566MG Mn72S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLQTWM2OD1{Mj63OlAyKM7:TR?= MXTTRW5ITVJ?
EFO-27 Mni0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHezOmdKSzVyPUKzMlA3PTFizszN NFjHfG1USU6JRWK=
NCI-H596 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXoTmNKSzVyPUKzMlg2OjdizszN NFXrdVJUSU6JRWK=
KS-1 Mni2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorUTWM2OD1{ND6yO|U6KM7:TR?= MmPVV2FPT0WU
8305C M4DIVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTyVlZKSzVyPUK0MlQxPDVizszN NGfkOJpUSU6JRWK=
A427 NX3mXlYxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTJ3LkCzNlMh|ryP MUjTRW5ITVJ?
COLO-800 Mnn2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrvPYFKSzVyPUK1MlExPjFizszN Mn;OV2FPT0WU
SJRH30 MkG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjjeZNKSzVyPUK1MlM6ODhizszN M4TLOnNCVkeHUh?=
MEL-HO NWrZUnpOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LnVWlEPTB;MkWuOFMyQSEQvF2= MYfTRW5ITVJ?
FTC-133 NFzRTFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{H1OGlEPTB;MkWuPFE5PiEQvF2= Ml3vV2FPT0WU
SF295 M2Syd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTJ4LkK5OkDPxE1? M2P2d3NCVkeHUh?=
SW1710 NEXRW41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPMTWM2OD1{Nj60NVI{KM7:TR?= M3LybHNCVkeHUh?=
EFM-19 NHPZOI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHlWW1uUUN3ME2yOk45OTR3IN88US=> MY\TRW5ITVJ?
NB10 M{jSe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfQToJUUUN3ME2yPE4zOjl5IN88US=> NUDQU41{W0GQR1XS
TK10 NFHWbI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTJ6LkKzPVkh|ryP NVn4folDW0GQR1XS
D-502MG NIfyUmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUftOIZYUUN3ME2yPE41KM7:TR?= MXTTRW5ITVJ?
EW-18 M3KzdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfRO5E3UUN3ME2yPE41Ozh4IN88US=> Mmq4V2FPT0WU
VMRC-RCZ NID6NZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;reGlEPTB;MkiuPVQyKM7:TR?= MXXTRW5ITVJ?
Ca9-22 MnPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTJ7LkS1OVch|ryP MnPkV2FPT0WU
KYSE-70 M2HzeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXwNXJRUUN3ME2yPU42Pzh4IN88US=> NYjQVY9[W0GQR1XS
A101D MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkflTWM2OD1{OT62OFczKM7:TR?= NVS0fm5UW0GQR1XS
WM-115 NV3YWIlrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnoZlV1UUN3ME2yPU44PjB5IN88US=> Mmi0V2FPT0WU
HCC2157 MkXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\6U2lEPTB;MkmuPFgxPyEQvF2= NUjFOIhYW0GQR1XS
TE-9 MkTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzITWM2OD1{OT64PFY2KM7:TR?= NV[5eXZFW0GQR1XS
K-562 Ml3aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XWXWlEPTB;M{CuNFk{OyEQvF2= NFXmdVBUSU6JRWK=
SN12C M{TIeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHOdWo4UUN3ME2zNE4yPDJ4IN88US=> NWjWTolqW0GQR1XS
ESS-1 NEnKSXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXGwUIFbUUN3ME2zNE41PzV7IN88US=> MmDFV2FPT0WU
K5 M{nOT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mor3TWM2OD1|MD63OlQh|ryP M{TtTHNCVkeHUh?=
J82 M3mxTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkX2TWM2OD1|MT6wPFk4KM7:TR?= NUHhPGNNW0GQR1XS
HOP-92 M2[1e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPrTWM2OD1|MT6xNVEyKM7:TR?= NWPNN2FXW0GQR1XS
NCI-H2228 M3vUTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;yTnA{UUN3ME2zNU4{Ojl4IN88US=> M3XTcXNCVkeHUh?=
OCI-AML2 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfaXo5KSzVyPUOxMlM3OSEQvF2= MYrTRW5ITVJ?
NCI-SNU-5 NXfme2lpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTNzLkixN|ch|ryP NHPW[lFUSU6JRWK=
A3-KAW NGfqXFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTNzLkmyOFMh|ryP M4S5bHNCVkeHUh?=
LCLC-103H MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTN{LkCxO|Eh|ryP M1mwfHNCVkeHUh?=
KY821 NIHmfHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4n3[2lEPTB;M{KuOlg5PCEQvF2= NFz1UpNUSU6JRWK=
JVM-2 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\GNGlEPTB;M{KuPVA4QSEQvF2= NVnC[2RHW0GQR1XS
Mo-T NYXVWIhjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFW4VYRKSzVyPUOzMlExODVizszN MVvTRW5ITVJ?
IA-LM NF;m[opIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TlUmlEPTB;M{OuNlc2KM7:TR?= MmDPV2FPT0WU
C8166 NFnLVmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHe1XnFKSzVyPUOzMlMyQTJizszN NWfBUFd{W0GQR1XS
TCCSUP MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zod2lEPTB;M{OuOFMxPyEQvF2= NFfUPGxUSU6JRWK=
JEG-3 MmX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonCTWM2OD1|Mz60O|Y5KM7:TR?= MlXJV2FPT0WU
MS-1 NEDYb3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fMR2lEPTB;M{OuOVU2OSEQvF2= NXjqd2U5W0GQR1XS
NCI-H1304 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmf5TWM2OD1|Mz61O|I2KM7:TR?= NXL1foR1W0GQR1XS
Ramos-2G6-4C10 NH33TmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3W3eGlEPTB;M{SuNFM{PSEQvF2= MWHTRW5ITVJ?
MDA-MB-453 NUHzfXlPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWntbmxjUUN3ME2zOE43Ozl3IN88US=> MYjTRW5ITVJ?
KYSE-520 NIPM[lFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzxTWM2OD1|ND63NVgyKM7:TR?= NYTJb2FoW0GQR1XS
SW900 MljlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonDTWM2OD1|ND64NVE2KM7:TR?= MoX4V2FPT0WU
HCC2998 M1[zOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTMendYUUN3ME2zOU4yPTJ7IN88US=> MYrTRW5ITVJ?
A2058 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkewTWM2OD1|NT62NFYyKM7:TR?= M3HkNHNCVkeHUh?=
OVCAR-3 MkToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\TNWlEPTB;M{[uNlA1PSEQvF2= NEjPXFJUSU6JRWK=
MOLT-4 M1LXW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTN4LkKyPVQh|ryP MoDKV2FPT0WU
CAPAN-1 NVrUNlBqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPvTWM2OD1|Nj60Olk6KM7:TR?= M1ftRnNCVkeHUh?=
SCC-9 NFP2eWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTN5LkSwNlch|ryP NFrUeW9USU6JRWK=
SF268 MlrWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\5dmZKSzVyPUO4MlM1OzNizszN NUSyTJFDW0GQR1XS
HGC-27 M2fjWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrGT5VKSzVyPUO4MlM4OTFizszN NFq3XpBUSU6JRWK=
DOHH-2 NYfI[4Y4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PxZmlEPTB;M{iuO|E2QCEQvF2= NYP1UoFrW0GQR1XS
KE-37 M1vVfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXCfXY1UUN3ME2zPE46QDJ6IN88US=> NEnjPHhUSU6JRWK=
MOLT-13 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTN7LkK1NFIh|ryP NEDtTVNUSU6JRWK=
ES1 NYX6bJhKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfYVVI{UUN3ME2zPU4{QDVizszN NGG2RYRUSU6JRWK=
SK-OV-3 NYjvSItxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MortTWM2OD1|OT65OlQ{KM7:TR?= MVnTRW5ITVJ?
SNU-449 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LVZWlEPTB;NECuNFc3PCEQvF2= M4LHOXNCVkeHUh?=
KYSE-510 NGm3UYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfnTnIyUUN3ME20NE4yOjl3IN88US=> MmK0V2FPT0WU
HL-60 Mof2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTRyLkm3PFMh|ryP NXHnVGJPW0GQR1XS
DJM-1 MoHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTRyLkm3PVkh|ryP MUHTRW5ITVJ?
TGBC11TKB MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml63TWM2OD12MT6wPVI3KM7:TR?= MXXTRW5ITVJ?
U-2-OS MmDUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{j6e2lEPTB;NEKuNlY1OSEQvF2= MXXTRW5ITVJ?
NCI-H2030 NVzZbXMyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\nfFRKSzVyPUSyMlQ{PjhizszN NIPyfoRUSU6JRWK=
LU-135 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnKxTWM2OD12Mj61OFQ4KM7:TR?= NVnDd3pCW0GQR1XS
ZR-75-30 NUfzSmZET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LyUmlEPTB;NEOuNFQ6OyEQvF2= M2jodXNCVkeHUh?=
GT3TKB Mn7SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;0cJZKSzVyPUSzMlI3PzlizszN MWfTRW5ITVJ?
RPMI-2650 NUW5dVA3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTR|Lke4NVYh|ryP MYnTRW5ITVJ?
SAS MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7MenNOUUN3ME20N{46PTN2IN88US=> Mon5V2FPT0WU
MDA-MB-231 NH20RlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2j3eWlEPTB;NEOuPVYxQSEQvF2= NF31S|RUSU6JRWK=
JVM-3 NYS4cHpRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljyTWM2OD12ND6wOVM{KM7:TR?= MVzTRW5ITVJ?
COLO-320-HSR MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTR2LkW2N|Mh|ryP M1yzfHNCVkeHUh?=
SNB75 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUT3UY53UUN3ME20OE43OTB3IN88US=> MYTTRW5ITVJ?
NCI-H441 NUDhN5loT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTR2LkmzNlgh|ryP NULzPWduW0GQR1XS
HCT-116 NXHlco5QT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13pbWlEPTB;NESuPVg3QCEQvF2= NGj6T3RUSU6JRWK=
NCI-H226 NX3teFFTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1z4b2lEPTB;NEWuOlM3QCEQvF2= NF;BelVUSU6JRWK=
CAL-33 MkDkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvySWFKSzVyPUS1MlkzOTdizszN MVfTRW5ITVJ?
NCI-H1437 NGfTSW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mli3TWM2OD12Nj6zNlEh|ryP NVvtcmd2W0GQR1XS
HCC1187 Mn;wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4mwemlEPTB;NE[uOFI2PSEQvF2= Mn6wV2FPT0WU
NUGC-3 NFjCXItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTR4LkW3NFkh|ryP M1Pj[HNCVkeHUh?=
T98G Ml65S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTR5LkW0O{DPxE1? M4DISXNCVkeHUh?=
OVCAR-8 NXmxVGY3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDSbm1KSzVyPUS3MlY5OyEQvF2= NFTWZVlUSU6JRWK=
LB2241-RCC MnzPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrWfpFKSzVyPUS3MlczPyEQvF2= NYDpSZlIW0GQR1XS
NCI-H358 NXPTXW9PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnyTWM2OD12OD6xNVUzKM7:TR?= M3zmfHNCVkeHUh?=
PANC-08-13 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUW2SXllUUN3ME20PE4yQDV|IN88US=> NYfZfFZvW0GQR1XS
KP-N-YN NV21dYNzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTR6LkKxNFIh|ryP NVT0V|RNW0GQR1XS
NCI-H1755 NX7lVmxYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTR6LkK3NlYh|ryP NYDHOZBPW0GQR1XS
NCI-N87 NIS2SVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzIOYtKSzVyPUS4MlI6QTFizszN MkjpV2FPT0WU

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
pFGFR2 / FGFR2 ; 

PubMed: 24968263     


PD173074 and MK2461 inhibit FGFR2 phosphorylation. Cells were treated for 1 hour with a titration of PD173074 as described in Materials and methods. Lysates were prepared and 50 ug protein was subjected to SDS-PAGE and western blotting with phospho Y653/654 FGFR and MAB6841 total FGFR2 antibody.

p-S6RP / p-PRAS40 / p-p105 NFKB / P105 NFKB / P50 NFKB / p-AMPK / p-CRK II / p-PDK1; 

PubMed: 24968263     


Time course of inhibition for multiple signaling proteins. NCI-H716 cells were treated with 100 nM PD173074 for the indicated times and signaling pathways were analyzed by SDS PAGE and western blotting. 100 nM PD173074 was selected because this amount caused full inhibition of pERK at the 2 hour time point. “p” indicates phosphoprotein, and the phosphorylation sites are listed in Methods. Terminology on the right side of figure groups proteins according to the time at which inhibition or protein loss occurs.

24968263
Growth inhibition assay
Cell viability; 

PubMed: 24968263     


B. PD173074 and MK2461 inhibit NCI-H716 cell growth. Cell lines were plated at 4000 cells/well and incubated overnight. NCI-H716 cells were treated with a titration of PD173074 as described in Materials and Methods. Cell growth was measured with Vialight reagent, and growth was presented relative to untreated cells. C. PD173074 and MK2461 selectively inhibit growth of NCI-H716 cells. Colon cancer cell lines listed were plated at 4000 cells/well and 24 hours later were treated with a titration of compounds. 4 days later cell growth was measured with vialight and IC50s were calculated from graph pad prism. 

24968263
In vivo Administration of PD173074 at 1 mg/kg/day or 2 mg/ka/day in mice can effectively block angiogenesis induced by either FGF or VEGF in a dose-dependent manner with no apparent toxicity. [1] PD173074 inhibits in vivo growth of mutant FGFR3-transfected NIH 3T3 cells in nude mice. Inhibition of FGFR3 by PD173074 delays tumor growth and increases survival of mice in a KMS11 xenograft myeloma model. [4] In the H-510 xenograft, oral aministration of PD173074 blocks tumor growth similar to that seen with single-agent cisplatin administration, increasing median survival compared with control sham-treated animals. In H-69 xenografts, PD173074 induces complete responses lasting >6 months in 50% of mice. These effects are correlated with increased apoptosis in excised tumors, but not a consequence of disrupted tumor vasculature. [5]

Protocol

Kinase Assay:[1]
+ Expand

In vitro kinase inhibition assays:

Assays using the full-length FGFR-1 kinase are performed in a total volume of 100 μL containing 25 mM HEPES buffer (pH 7.4), 150 mM NaCl, 10 mM MnCl2, 0.2 mM sodium orthovanadate, 750 μg/mL concentration of a random copolymer of glutamic acid and tyrosine (4:1), various concentrations of PD173074 and 60 to 75 ng of enzyme. The reaction is initiated by the addition of [γ-32P]ATP (5 μM ATP containing 0.4 μCi of [γ-32P]ATP per incubation), and samples are incubated at 25°C for 10 minutes. The reaction is terminated by the addition of 30% trichloroacetic acid and the precipitation of material onto glass-fiber filter mats. Filters are washed three times with 15% trichloroacetic acid, and the incorporation of [32P] into the glutamate tyrosine polymer substrate is determined by counting the radioactivity retained on the filters in a Wallac 1250 betaplate reader. Nonspecific activity is defined as radioactivity retained on the filters following incubation of samples without enzyme. Specific activity is determined as total activity (enzyme plus buffer) minus nonspecific activity. The concentration of PD173074 that inhibits FGFR-1 enzymatic activity by 50% (IC50) is determined graphically.
Cell Research:[4]
+ Expand
  • Cell lines: KMS11 and KMS18
  • Concentrations: Dissolved in DMSO, final concentrations ~100 nM
  • Incubation Time: 48 hours
  • Method: Cells are incubated with increasing concentrations of PD173074 in the presence of aFGF/heparin for 48 hours. The percentage of viable cells is determined by MTT.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: Swiss Webster mice with induced corneal angiogenesis
  • Formulation: Prepared in sterile fashion
  • Dosages: ~2 mg/kg/day
  • Administration: Administered intraperitoneally
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (190.95 mM)
Ethanol 100 mg/mL (190.95 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+corn oil
For best results, use promptly after mixing.
15mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 523.67
Formula

C28H41N7O3

CAS No. 219580-11-7
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What is the half-life of PD173074(S1264) in vivo?

  • Answer:

    According to literature research, PD173074 is given twice daily because it has a short half-life in vivo, please refer to the following link for detailed pharmacokinetic information (Supplementary Figure 8B): http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3990281/#!po=50.0000.

FGFR Signaling Pathway Map

FGFR Inhibitors with Unique Features

Related FGFR Products

Tags: buy PD173074 | PD173074 supplier | purchase PD173074 | PD173074 cost | PD173074 manufacturer | order PD173074 | PD173074 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID